Stephenson Pamela's Form 4/A amendment
AmendedAlbireo Pharma, Inc. (ALBO) · filed Jan 9, 2023
- Accession no.
- 0001209191-23-002636
- Filed
- Jan 9, 2023
- Trade date
- Dec 27, 2022
- Filing delay
- 13 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Dec 27, 2022
This filing lists 1 non-derivative transaction. Open-market sales total $8.94K. It was filed 13 days after the trade.
This amendment replaces 0001209191-22-062701 (filed Dec 27, 2022).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Stephenson PamelaCIK 0001767650 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 27, 2022 | Common Stock | SSaleDisposed | −469 | $19.06 | −$8,939.14 | 44,631 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
- F2
Represents 18,374 shares of common stock and 26,257 restricted stock units.
Remarks
This amended Form 4 is being filed solely to correct the numbers of shares disclosed in column 5 of Table I and footnote 3, as the reporting person did not acquire 547 shares of common stock under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan on May 31, 2022.